| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2017: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2016: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
|---|
| Outline of Final Research Achievements |
We have performed basic research using genetically modified mice and confirmed that CyPA is an important protein for the development of pulmonary hypertension (PH). Next, we developed a method for measuring the plasma CyPA concentration in patients with PH and confirmed that the concentration was elevated in patients compared with healthy controls. Moreover, patients with high plasma CyPA showed poorer prognosis compared with those with low CyPA levels. Third, we performed screening of therapeutic molecules focusing on inhibition of CyPA and extracellular CyPA receptor (basigin) by using high throughput screening system, and validated the effectiveness in animal models of PH.
|
